EVFM — Evofem Biosciences Balance Sheet
0.000.00%
- $1.19m
- $52.94m
- $19.36m
- 14
- 80
- 61
- 51
Annual balance sheet for Evofem Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 48.9 | 7.73 | 2.77 | 0 | 0.127 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.32 | 6.45 | 1.13 | 5.74 | 9.83 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 97.7 | 30.1 | 12.7 | 9.21 | 13.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 11.2 | 11.2 | 8.35 | 1.31 | 0.547 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 110 | 42.5 | 25.2 | 10.6 | 23.8 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 77.3 | 138 | 93.8 | 72.5 | 80.4 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 109 | 142 | 97 | 72.5 | 90.3 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1.35 | -99.6 | -71.8 | -61.9 | -66.5 |
| Total Liabilities & Shareholders' Equity | 110 | 42.5 | 25.2 | 10.6 | 23.8 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |